Twist Bioscience officer sells shares to cover taxes

Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, reported a small mandated share sale linked to equity compensation.

Rhea-AI Filing Summary

Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, reported a small mandated share sale linked to equity compensation. On this Form 4, he disposed of 246 shares of common stock at $46.426 per share on March 6, 2026, and held 54,799 shares afterward.

According to the footnote, the sale was required to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity plans. The transaction was executed as a “sell to cover” event and is characterized as non-discretionary rather than an elective open-market trade.

Insider Trade Summary

Net Seller: 246 shares

Net Sell 1 txn

Insider WERNER ROBERT F.

Role Chief Accounting Officer

Sold 246 shs ($11K)

Type	Security	Shares	Price	Value
Sale	Common Stock	246	$46.426	$11K

Holdings After Transaction: Common Stock — 54,799 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Twist Bioscience (TWST) report on this Form 4?

Twist Bioscience reported that Chief Accounting Officer Robert F. Werner disposed of 246 shares of common stock on March 6, 2026. The shares were sold at $46.426 each in a mandated sell-to-cover transaction tied to Restricted Stock Unit vesting and related tax obligations.

Was the Twist Bioscience (TWST) insider share sale a discretionary trade?

The filing states the sale was not discretionary. Shares were sold solely to cover tax withholding obligations from vesting Restricted Stock Units, under the company’s equity incentive plan “sell to cover” election, meaning the officer did not choose the timing or amount as an investment decision.

How many Twist Bioscience (TWST) shares did the officer sell and at what price?

Chief Accounting Officer Robert F. Werner sold 246 Twist Bioscience common shares at $46.426 per share. This small transaction was executed as part of a mandated sell-to-cover process related to equity award vesting and associated tax withholding requirements, rather than a standard open-market sale.

How many Twist Bioscience (TWST) shares does the insider hold after this transaction?

After the transaction, Robert F. Werner directly held 54,799 Twist Bioscience common shares. This context shows the reported sale covered only a small fraction of his total position, consistent with a routine tax withholding event rather than a significant change in ownership stake.

What type of compensation event triggered the Twist Bioscience (TWST) insider sale?

The transaction was triggered by the vesting of Restricted Stock Units granted under Twist Bioscience’s equity incentive plans. When the RSUs vested, a portion of shares had to be sold automatically to satisfy tax withholding obligations, resulting in the reported sell-to-cover share disposition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WERNER ROBERT F.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		S		246(1)	D	$46.426	54,799	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Robert F. Werner	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.